Abstract:The aim of this study was to investigate the possibility of using sperm function tests (hypoosmotic swelling test [HOS], aniline blue [AB] staining test, and sperm chromatin dispersion [SCD]) to predict intrauterine insemination [IUI] success rate. A total of 243 couples with mild male factor or unexplained male infertility who underwent IUI were evaluated prospectively. The results of basic sperm analysis and sperm function tests were compared between pregnant or nonpregnant groups. The HOS (11.9 ± 9.6% vs. 1… Show more
“…Previous studies showed that physiopathological conditions such as varicocele may lead to a decreased sperm protamination (Irez et al, 2018;Talebi et al, 2008) and that an altered P1/P2 ratio increases the presence of immature sperm cells and sperm DNA damage, leading to infertility (Castillo et al, 2011;García-Peiró et al, 2011;Torregrosa et al, 2006 (Nasr-Esfahani et al, 2005;Tarozzi et al, 2009). Then, the evidence presented here shows that CMA3 test would be a suitable diagnostic test for male factor related to a lack of pregnancy and miscarriage risk.…”
Section: Clinical Significance Of Dna Condensationmentioning
confidence: 54%
“…While infertility is present in between 7% and 15% of couples in reproductive age, a male factor is present in half of the infertile couples (Louis et al, 2013; WHO, 2010). Sperm cell provides the male genome complement, but studies in the last decade show that it also provides important epigenetic signals (Krausz et al, 2015; Sharma et al, 2019), crucial nRNAs necessary for the first stages of embryogenesis and the centriole that will be used in zygote development (Fishman et al, 2018; Giacone et al, 2019; Zhang et al, 2019).…”
The aim of the present work is to characterize the relationship between sperm protamine deficiency and single-and double-stranded DNA damage and to assess the diagnostic potential of chromomycin A3 (CMA3). For that purpose, semen samples from 90 human males with different clinical features were included (fertile donors, patients with recurrent pregnancy loss [RPL], and infertile patients). DNA condensation was analyzed by CMA3 and different types of DNA fragmentation were analyzed through the comet assay. A positive correlation between DNA condensation and single-stranded DNA fragmentation was found (Rs = .456; p = .05). CMA3 presented differences between fertile donors and all other groups (p < .001). Interestingly, patients with RPL, who were able to achieve a pregnancy, and infertile patients showed similar values of CMA3 (p > .05). Receiver operating characteristic curves and the profiles obtained by the combination of Comet assays and CMA3 indicate that the CMA3 test may be an interesting approach to distinguish those subjects with higher pregnancy loss risk from fertile donors (CMA3 area under the curve 0.928, with a confidence interval of 0.849-1.000). The present work shows that DNA condensation is related to oxidative damage, which affects mainly protamine-rich regions. The profiles observed in different clinical groups showed that CMA3 might be useful for the diagnosis of RPL risk when combined with Comet assays.
“…Previous studies showed that physiopathological conditions such as varicocele may lead to a decreased sperm protamination (Irez et al, 2018;Talebi et al, 2008) and that an altered P1/P2 ratio increases the presence of immature sperm cells and sperm DNA damage, leading to infertility (Castillo et al, 2011;García-Peiró et al, 2011;Torregrosa et al, 2006 (Nasr-Esfahani et al, 2005;Tarozzi et al, 2009). Then, the evidence presented here shows that CMA3 test would be a suitable diagnostic test for male factor related to a lack of pregnancy and miscarriage risk.…”
Section: Clinical Significance Of Dna Condensationmentioning
confidence: 54%
“…While infertility is present in between 7% and 15% of couples in reproductive age, a male factor is present in half of the infertile couples (Louis et al, 2013; WHO, 2010). Sperm cell provides the male genome complement, but studies in the last decade show that it also provides important epigenetic signals (Krausz et al, 2015; Sharma et al, 2019), crucial nRNAs necessary for the first stages of embryogenesis and the centriole that will be used in zygote development (Fishman et al, 2018; Giacone et al, 2019; Zhang et al, 2019).…”
The aim of the present work is to characterize the relationship between sperm protamine deficiency and single-and double-stranded DNA damage and to assess the diagnostic potential of chromomycin A3 (CMA3). For that purpose, semen samples from 90 human males with different clinical features were included (fertile donors, patients with recurrent pregnancy loss [RPL], and infertile patients). DNA condensation was analyzed by CMA3 and different types of DNA fragmentation were analyzed through the comet assay. A positive correlation between DNA condensation and single-stranded DNA fragmentation was found (Rs = .456; p = .05). CMA3 presented differences between fertile donors and all other groups (p < .001). Interestingly, patients with RPL, who were able to achieve a pregnancy, and infertile patients showed similar values of CMA3 (p > .05). Receiver operating characteristic curves and the profiles obtained by the combination of Comet assays and CMA3 indicate that the CMA3 test may be an interesting approach to distinguish those subjects with higher pregnancy loss risk from fertile donors (CMA3 area under the curve 0.928, with a confidence interval of 0.849-1.000). The present work shows that DNA condensation is related to oxidative damage, which affects mainly protamine-rich regions. The profiles observed in different clinical groups showed that CMA3 might be useful for the diagnosis of RPL risk when combined with Comet assays.
“…We straightened this multiple regression analysis results by ROC curve that permitted us to find an AB test cut-off of 19% predictive for sperm count and motility, but not for morphology. Whereas several authors found an AB test cut-off in relation with clinical results [26,41], we identified a cut-off value in relation to semen parameters was considered to be significant data showed a correlation between a positive AB test and impaired sperm parameters: poorly packed sperm chromatin makes DNA more susceptible to reactive oxygen species (ROS) attack [16]. Oxidative stress condition has a negative effect both on mitochondrial functionality and DNA: this leads to a decrease in sperm motility and an impairment of DNA integrity [53].…”
Section: Discussionmentioning
confidence: 99%
“…On the day of insemination, all subjects underwent semen analysis: fresh semen was collected in a sterile jar by masturbation after 3-5 days of sexual abstinence. Semen analysis has been performed following the WHO 2010 [28] at 5° percentile: semen volume, 1,5 (1,4-1,7) ml; total sperm number, 39 (33)(34)(35)(36)(37)(38)(39)(40)(41)(42)(43)(44)(45)(46) million per ejaculate, sperm concentration, 15 (12-16) million per ml; progressive motility, 32% (31)(32)(33)(34); total (progressive, non-progressive) motility, 40% (38)(39)(40)(41)(42); morphology 4,0% (3,0-4,0). Swim-up was performed for semen preparation.…”
Section: Semen Assessment and Preparationmentioning
“…Histone content assay using aniline blue staining was carried out to assess the nuclear maturity status of the spermatozoa. Slides were prepared by smearing raw specimen, air-drying, and fixing in 4% paraformaldehyde solution for 10 min, and then staining for 5 min in 5% aqueous aniline blue solution (pH 3.5) [ 28 , 29 ]. Spermatozoa were analyzed under bright-field illumination at 1000× magnification.…”
Purpose
To characterize, by specific biomarkers and nucleic acid sequencing, the structural and genomic sperm characteristics of partial (PG) and complete globozoospermic (CG) men in order to identify the best reproductive treatment.
Methods
We assessed spermatozoa from 14 consenting men ultrastructurally, as well as for histone content, sperm chromatin integrity, and sperm aneuploidy. Additional genomic, transcriptomic, and proteomic evaluations were carried out to further characterize the CG cohort. The presence of oocyte-activating sperm cytosolic factor (OASCF) was measured by a phospholipase C zeta (PLCζ) immunofluorescence assay. Couples were treated in subsequent cycles either by conventional ICSI or by ICSI with assisted gamete treatment (AGT) using calcium ionophore (Ionomycin, 19657, Sigma-Aldrich, Saint Louis, MO, USA).
Results
Ultrastructural assessment confirmed complete acrosome deficiency in all spermatozoa from CG men. Histone content, sperm chromatin integrity, and sperm aneuploidy did not differ significantly between the PG (n = 4) and CG (n = 10) cohorts. PLCζ assessment indicated a positive presence of OASCF in 4 PG couples, who underwent subsequent ICSI cycles that yielded a 36.1% (43/119) fertilization with a 50% (2/4) clinical pregnancy and delivery rate. PLCζ assessment failed to detect OASCF for 8 CG patients who underwent 9 subsequent ICSI cycles with AGT, yielding a remarkable improvement of fertilization (39/97; 40.2%) (P = 0.00001). Embryo implantation (6/21; 28.6%) and clinical pregnancies (5/7; 71.4%) were also enhanced, resulting in 4 deliveries. Gene mutations (DPY19L2, SPATA16, PICK1) were identified in spermatozoa from CG patients. Additionally, CG patients unable to sustain a term pregnancy had gene mutations involved in zygote development (NLRP5) and postnatal development (BSX). CG patients who successfully sustained a pregnancy had a mutation (PIWIL1) related to sperm phenotype. PLCZ1 was both mutated and underexpressed in these CG patients, regardless of reproductive outcome.
Conclusions
Sperm bioassays and genomic studies can be used to characterize this gamete’s capacity to support embryonic development and to tailor treatments maximizing reproductive outcome.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.